• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Guidant gets probation in defib plea deal

Guidant gets probation in defib plea deal

January 13, 2011 By MassDevice staff

BSX, Guidant logos

A Minnesota federal judge added three years of probation to a $296 million plea deal between Guidant Corp. and the U.S. Justice Dept. over faulty implantable defibrillators.

Last spring, Judge Donovan Frank spiked a $296 million agreement involving a guilty plea by the now-Boston Scientific Corp. (NYSE:BSX) subsidiary, saying the deal didn’t go far enough to address Guidant’s penchant for concealing problems with the devices.

In February 2002, Guidant discovered a design flaw in the Ventak device, after receiving reports of failures. By April 2002, according to court documents, it had fixed the flaws and begun producing a corrected version of the device — but didn’t recall the defective products.

The company continued to sell the defective devices without revealing their design flaws and malfunctions. Prosecutors allege that the problems with the device killed at least 13 people — including one in 2009 — beginning when 21-year-old Joshua Oukrop’s Ventak Prizm 2 DR short-circuited in March 2005.

In rejecting the plea deal last April, Frank ordered Guidant to detail its efforts to right the ship. After reviewing the company’s submission, he added the three years of probation, saying he might consider a shorter term if Guidant lives up to its pledges.

Guidant LLC must pay fines of $254 million and forfeit $42 million for selling some of the devices after failing to filed a safety report with the Food & Drug Administration. Boston Scientific agreed to those provisions early in April 2009, but Frank, of the U.S. District Court for Minnesota, shot the deal down.

“The judge imposed the penalty in the plea agreement, which we were asking for. And he imposed a further penalty,” assistant U.S. attorney Robert Lewis told the Pioneer Press. “We think justice has been served.”

For its part, Boston Scientific stood up for its errant division in a statement to the newspaper.

“The company is pleased that this issue is now resolved,” BSX said. “We continue to believe that Guidant and its employees acted in good faith and with the intention of complying with applicable laws and regulations.”

Boston Scientific shares were were down slightly to $7.44 in pre-market trading.

Filed Under: Business/Financial News, Legal News, News Well Tagged With: Boston Scientific, Cardiac Rhythm Management, Guidant Corp.

More recent news

  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure
  • NanoVibronix enters into $50M financing agreement

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy